The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis

Çolpan, Leyla; Gür, Ali; Çevik, Remzi; Nas, Kemal; Saraç, Ayşegül Jale

doi:10.1016/j.maturitas.2004.07.013

Cited by 7 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that calcitonin, a 32‐amino acid peptide hormone, has a hypocalcemic action and that calcitonin can mineralize bones by suppressing the activities of osteoclasts. This drug is useful for the treatment of human osteoporosis [49–51]. We recently obtained evidence that the strength of the inhibitory action of melatonin on scale osteoclasts was almost equal to that of salmon and eel calcitonins (N. Suzuki, personal communication).…”

Section: Discussionmentioning

confidence: 99%

Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases

Suzuki

Somei

Kitamura

et al. 2007

Journal of Pineal Research

View full text Add to dashboard Cite

The teleost scale is a calcified tissue that contains osteoclasts, osteoblasts, and bone matrix, all of which are similar to those found in mammalian membrane bone. Using the goldfish scale, we recently developed a new in vitro assay system and previously demonstrated that melatonin suppressed both osteoclastic and osteoblastic activities in this assay system. In mammals, 2-bromomelatonin possesses a higher affinity for the melatonin receptor than does melatonin. Using a newly developed synthetic method, we synthesized 2-bromomelatonin, 2,4,6-tribromomelatonin and novel bromomelatonin derivatives (1-allyl-2,4,6-tribromomelatonin, 1-propargyl-2,4,6-tribromomelatonin,

show abstract

Section: Discussionmentioning

confidence: 99%

Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases

Suzuki

Somei

Kitamura

et al. 2007

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…The 12 clinical randomized controlled trials included in this systematic evaluation included 1068 patients, all of whom were patients with primary osteoporosis. One study [9] referred to Chinese diagnostic criteria,8 studies [6,7,8,10,11,13,14,15] refer to WHO-recommended diagnostic criteria. Two studies [5,16] are self-designed diagnostic criteria.…”

Section: Basic Characteristics Of the Literature Included 221 Research Targetmentioning

confidence: 99%

“…4 studies [6,7,8,15] reported bone mineral density of the hip (femoral neck, intertrochanteric, and ward triangle). 5 studies [5,6,10,12,14] reported Serum calcium levels. 2 studies [5,14] reported Serum phosphorus level.…”

Section: Outcome Indicatorsmentioning

confidence: 99%

“…Therefore, this paper talks about the e cacy and safety analysis of the randomized controlled trials by searching for intranasal salmon calcitonin. Twelve articles about intranasal salmon calcitonin were obtained by searching each database [5,6,15,16,[7][8][9][10][11][12][13][14]. This paper gives a systematic evaluation and meta-analysis of this literature to provide an objective basis for clinical medication.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Meta-analysis of the Therapeutic Effect of Intranasal Salmon Calcitonin on Osteoporosis

Li¹,

Gong²

2021

Preprint

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of intranasal salmon calcitonin in the treatment of osteoporosis.Methods: eight Chinese and English databases were searched by electronic search (from the establishment of the database to October 2019). The literature was screened according to the inclusion criteria and exclusion criteria, the quality was evaluated according to Cochrane software, and the Review Manager 5.2 software was used for statistical analysis. Results: a total of 374 documents were retrieved and 12 (12 original studies) were included after the screening, with a total sample capacity of 1068 cases. Meta-analysis showed that the intranasal salmon calcitonin had obvious advantages in reducing blood calcium, improving the ratio of serum creatinine and alkaline phosphatase. In addition, The intranasal, salmon calcitonin had no obvious advantages in other indicators, It can't be illustrated that the combination of BCS and other conventional drugs is more effective than the simple use of conventional drugs. Conclusion: The intranasal salmon calcitonin is superior to conventional drugs in reducing blood calcium, increasing creatinine ratio, and alkaline phosphatase, but its advantages in other indicators such as improving the bone density of lumbar vertebrae and hip have not been confirmed, and it is not clear that the combination of intranasal salmon calcitonin and other conventional drugs is better than the simple conventional drugs.

show abstract

“…Elcatonin is a potent agent which increases bone density and has been widely used in the treatment of postmenopausal osteoporosis for many years over the world. It inhibits bone resorption by a direct action on osteoclasts ( Colpan et al, 2005 ;Arisawa et al, 2008 ). In vitro and in vivo studies have shown that elcatonin stimulates the growth of bone tissue ( Chesnut et al, 2005 ).…”

mentioning

confidence: 99%

The rhPTH (1–34), But not Elcatonin, Increases Bone Anabolic Efficacy in Postmenopausal Women with Osteoporosis

Zhang

Yang

Liu

et al. 2012

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Purpose: Intermittent administration of recombinant human PTH [rhPTH (1?34)] exerts an osteoanabolic effect characterized by direct effects on bone formation, increases bone density, and reduces fracture risk. This study was to investigate the anabolic effects of rhPTH(1?34) on postmenopausal osteoporosis in an Asian population and compare the time course and alteration in bone turnover marker (BTM) during rhPTH(1?34) and elcatonin treatment. Methods: 124 women with postmenopausal osteoporosis were enrolled in this prospective, open-label, active-controlled trial. The patients randomized to subcutaneous rhPTH(1?34) (20?ug, once daily) or elcatonin (200U, once week) injections for 12 months. Biochemical markers of bone formation (bone specific alkaline phosphatase [BSAP]), and bone resorption maker (serum C-telopeptide of type I collagen [CTX-I] were measured at baseline and at 0, 6, and 12 months. Results: At 12 months, rhPTH (1?34) significantly increased lumbar spine BMD significantly compared with baseline, whereas elcatonin was ineffective. BSAP levels were gradually increased in almost all rhPTH(1?34)-treated subjects and at the end of the study, the percentage of subjects with BSAP above the postmenopausal reference interval was gradually increased as high as 91.5% at month 12. Opposite trends in percentages for CTX-I was observed in rhPTH(1?34). With rhPTH(1?34), but not elcatonin, there were significant positive correlations between ratio of BSAP and CTX-I and bone mineral density (BMD) (r=0.318) at the end of month 12. Both treatments were well tolerated and there were no significant differences detected between the 2 groups in the proportion of any adverse events and any serious adverse events. Conclusions: rhPTH (1?34) has more positive effects on bone formation than elcatonin for postmenopausal women with osteoporosis and was proved to be safe and well tolerated. The ratio of BSAP and CTX-I may be a useful indicator for positive bone formation. Registration: Clinical trial registration: ChiCTR-TRC-11001331; Retrospective registered on May 3, 2011. http://apps.who.int/trialsearch/Trial.aspx?TrialID=ChiCTR-TRC-11001313.

show abstract

The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis

Cited by 7 publications

References 36 publications

Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases

Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases

A Meta-analysis of the Therapeutic Effect of Intranasal Salmon Calcitonin on Osteoporosis

The rhPTH (1–34), But not Elcatonin, Increases Bone Anabolic Efficacy in Postmenopausal Women with Osteoporosis

Contact Info

Product

Resources

About